Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02419118
- Locations
- 🇩🇰
Department of Hematology Vejle Hospital, Vejle, Denmark
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 90
- Registration Number
- NCT02415413
- Locations
- 🇪🇸
Hospital Clínico San Carlos, Madrid, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 316
- Registration Number
- NCT02406144
- Locations
- 🇪🇸
Hospital de La Santa Creu I Sant Pau, Barcelona, Spain
🇪🇸Hospital Universitari Mútua de Terrasa, Barcelona, Spain
🇪🇸Hospital Vall D'Hebron, Barcelona, Spain
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 81
- Registration Number
- NCT02399085
- Locations
- 🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇵🇱Szpital Wojewodzki Nr 1 im. Fryderyka Chopina w Rzeszowie, Rzeszow, Poland
🇺🇸Cancer Care - Torrance Memorial Physician Network, Redondo Beach, California, United States
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT02389543
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
- Conditions
- Plasma Cell MyelomaResidual Disease
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 42
- Registration Number
- NCT02389517
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
- Conditions
- Multiple Myeloma
- Interventions
- Drug: LenalidomideDrug: ElotuzumabDrug: BortezomibDrug: DexamethasoneProcedure: Stem Cell Mobilization
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02375555
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Lenalidomide and Obinutuzumab for Previously Untreated CLL
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- University of California, San Diego
- Registration Number
- NCT02371590
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid
- Interventions
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 11
- Registration Number
- NCT02370888
- Locations
- 🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States
Evaluation of the Immune Restoration Potential Of Lenalidomide
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- University of California, San Diego
- Registration Number
- NCT02371577
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.